Advicenne Achieves Notable Sales Growth in 2024
Advicenne, a prominent specialty pharmaceutical company listed on Euronext Growth Paris under the ticker ALDVI, has announced a remarkable achievement in its financial performance for the 2024 fiscal year. The company reported gross sales of €4.8 million, reflecting a robust increase of 9.2% compared to the previous year. This surge underscores Advicenne's commitment to developing innovative treatments for rare renal diseases.
Sales Breakdown and Product Performance
The growth in sales can largely be attributed to Advicenne's flagship product, Sibnayal®, which generated gross sales amounting to €2.2 million, marking an impressive rise of nearly 14%. Notably, sales of Sibnayal® soared by 40% within France, indicating strong market resonance and a significant uptick in demand since the beginning of the second half of 2024.
Estimations from Commercial Partners
In addition to its direct sales, Advicenne expects to achieve approximately €4.1 million in sales through its commercial partners in territories managed by those partners. This figure adds to the projected total end-market sales of Sibnayal® estimated at around €6.0 million across Europe and the Middle East, reflecting a staggering 135% growth from 2023.
Other Products in the Range
The company reported gross sales of €2.0 million from its other products, Likozam® and Levidcen®, with detailed performance highlighted in the annual report. Leveraging a successful product portfolio, Advicenne is positioning itself strongly in the specialty pharmaceutical sector.
Cash Position and Financial Outlook
As of the end of 2024, Advicenne maintained a solid cash position of €3.2 million, indicating a stable financial horizon. Excluding exceptional items, this amount provides a cash runway extending until the end of the second quarter of 2025. This tense financial footing follows the agreements with Primex Pharmaceuticals AG, marking a significant milestone in Advicenne's strategy for sustained growth and development.
About Advicenne
Founded in 2007, Advicenne specializes in developing new treatments in the field of Nephrology. The company has made tremendous strides with its primary product Sibnayal®, approved for treating distal renal tubular acidosis (dRTA) in both the EU and Great Britain. Advicenne is also advancing its second product, ADV7103, which is in late-stage development for cystinuria in Europe, as well as both dRTA and cystinuria in the United States and Canada. With its headquarters in Paris and listed on Euronext Growth Paris since 2022, Advicenne is well-positioned for continued growth and innovation.
Frequently Asked Questions
What were Advicenne's gross sales for 2024?
Advicenne reported gross sales of €4.8 million for the 2024 financial year.
How much did Sibnayal® contribute to sales in 2024?
Sibnayal® generated gross sales of €2.2 million, an increase of almost 14% compared to the previous year.
What is Advicenne's current cash position?
As of December 31, 2024, Advicenne had a cash position of €3.2 million.
What are the future prospects for Advicenne's products?
The company's products are expected to see growth, with total end-market sales of Sibnayal® in Europe and the Middle East estimated at €6.0 million for 2024.
When was Advicenne founded?
Advicenne was founded in 2007 and has focused on developing innovative treatments for rare renal diseases.
